Q-omics provides the consensus-scored KRT89P profile across patient tissues and cancer cell-line models. KRT89P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KRT89P is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, KRT89P RNA expression shows 11,901 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where KRT89P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT89P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT89P survival associations across molecular data types. KRT89P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT89P RNA expression–survival associations across cancer types. High KRT89P expression shows unfavorable associations in STAD, KIRP and ACC, but favorable associations in BLCA, UCS and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for KRT89P RNA expression.
This table summarizes KRT89P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT89P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT89P shows lower tumor expression in THCA and STAD and higher tumor expression in BLCA, BRCA, LUAD and UCEC. The THCA box plot shows higher KRT89P RNA expression in normal versus tumor tissue (log2 FC = −1.777, t-test p < 0.001).
This table shows molecular features associated with KRT89P in patient tissues and cancer cell lines. In patient samples, KRT89P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
